Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Don Walster who wrote (994)	7/14/1998 4:57:00 PM
From: yosi s	Respond to of 1491

Globes article also quoted potential sales 500 M to 1 billion, Just be need to wait for phase 2 study to be open and the stock will see new highs, so far all the news from PARS is positive . Too bad that the price has droped. but that happened before. Best regards Yosi.

To: Don Walster who wrote (994)	7/14/1998 5:32:00 PM
From: NeuroInvestment	Read Replies (2) \| Respond to of 1491

1)If Schickler indeed told the Globe reporter ( I certainly hope not) that it would take 3-4 years to submit an NDA, Pharmos needs to buy better consultation regarding trial design and execution. There is no way, IF HU-211 behaves as well as many observers expect, that it should take that long. If the Phase II results are positive (and this does not require .05 statistical significance, with these small cohort sizes, consistent trends plus safety will suffice), that should garner a solid partner. By solid partner, I refer to a company willing/able to start a Phase III before the end of 1Q:99 (they will have to wait for the final cohort to complete in order to select the best dose for the Phase III). With enough sites on board, an 800-1000 pt Ph III could be run in 12-15 months.The greater the relative impact of HU211, the smaller the sample size needed for PhIII (though reducing it too far would risk the kinds of statistical glitches that have plagued Interneuron's stroke trials). With data analysis and NDA preparation taking around 6 months, the NDA should be submitted by the end of 2000...2.5 years from now. There are best-case, more risky scenarios that could accelerate it slightly (e.g. a positive interim analysis), but this is not an unreasonable timeframe which assumes a modest magnitude of therapeutic effect. NeuroInvestment (www.neuroinv.com)